C-erbB3. a new member of the erbB type I family of tyrosine kinase receptors. has been mapped to human chromosome 12qll-13 ). However. the related epidermal growth factor receptor (EGFR) is located on chromosome 7pl2-13 (Spurr et al. 1984 ) and the c-erbB2 gene on 17pl'-2 1.3 (Coussens et al. 1985 . The gene for the cerbB3 receptor is transcribed into a 6.2-kb mRNA. which is translated into the protein and modified by glycosvlation to give a mature protein of about 160 kDa (Plowman et al. 1990: Prigent and . Recently. it has been shown that heregulilnneu differentiation factor (NDF) binds to and stimulates the tyrosine kinase activity of c-erbB3 (Carrawav et al. 1994 ).
Expression of c-erbB3 has been detected in normal human adult and fetal tissues using polvclonal antibodies ). Rajkumar et al (1993) have described the production of a monoclonal antibody (RTJI) that is specific for c-erbB3 protein and reported positive immunostaining in a series of gastrointestinal tract tumours. Other studies have also demonstrated overexpression of c-erbB3 protein in breast carcinomas (Lemoine et al. 1992a : Gasparini et al. 1994 : Quinn et al. 1994 : Travis et al. 1996 . pancreatic cancers (Lemorne et al. 1992b ). gastric cancers (Sanidas et al. 1993) . cenical cancer (Hunt et al. 1995 . prostate cancer (Poller et al. 1992) . bladder cancer (Rajkumar et al. 1996) and ox-arian carcinomas (Mandai et al. 1994 : Simpson et al. 1995 .
Expression of EGFR and c-erbB2 receptors and the other members of the erbB familv has been extensivelv studied in many different tumours. and it has been found that their oxerexpression is associated w-ith poor prognosis (Lofts and Gullick. 1991: Gullick. 1991) . Elevated levels of EGFR and c-erbB2 has-e been found in breast carcinomas and are often found to be associated with poor prognosis (Sainsburx et al. 1987 : Costa et al. 1988 . Currently. there is little information axailable regarding the expression of c-erbB3 protein in formalin-fixed and paraffin-embedded primary breast carcinomas. As breast cancer is an important disease in Malaysia. especially in younger women. we used this study to evaluate the c-erbB3 expression in Malavsian breast cancer patients. The indirect immunoperoxidase method wvas used to examine the expression of c-erbB3 protein in breast carcinoma tissues fixed in formalin. We used two different types of monoclonal antibodies. RTJI (IgM) and RTJ2 (IgG1 The colour reaction was developed by incubating the sections with the AEC (3-amino-9-ethylcarbazole) chromogen (Dako) and counterstained with Mayer's haematoxylin (Fluka. France). The slides were mounted in aqueous mounting media and examined under the microscope. Immunostaining was also performed for EGFR (dilution 1:15, 1 h), c-erbB2 (dilution 1:80, 1.5 h). cathepsin-D (dilution 1:20, 1 h). p53 and oestrogen receptor (dilution 1:20. 2 h). All the antibodies were diluted in 1% BSA (bovine serum albumin. Sigma, USA). For p53 and oestrogen receptor, we used microwave treatment to obtain optimal staining intensity.
Initially, the sections were microwaved twice in 10 mM sodium citrate buffer (pH 6.0) for 5 min. The slides were cooled at room temperature for 20 min and washed in PBS before incubating with the primary antibody. T'he rest of the staining procedures were followed as above. Breast carcinoma tissues known to react with the marker were used as positive controls and incubated in each batch of staining. As for negative control, the primary antibody was omitted and replaced with PBS and negative control antibodies mouse IgGl (clone DAK-GOI, Dako) and IgM (clone DAK-G08, Dako). The antibodies were adjusted to the same concentration as the primary antibody.
Scoring and statistical analysis
The staining for c-erbB3 was cytoplasmic and was assessed according to the method descnbed by Quinn et al (1994) . Negative staining or equivocal staining was considered as less than normal expression, weak but defmnite positive staining was considered to represent normal expression and strong, granular staining indicated overexpression. However, for the purpose of statistical analysis. only the intensity of staining was considered. Strong membrane staining for c-erbB2 and epidermal growth factor receptor (EGFR) and strong cytoplasmic staining for cathepsin-D were considered to represent overexpression of the gene product. Tumours that exhibited strong positivity for c-erbB3. c-erbB2, EGFR and cathepsin-D were included in statistical analysis. For p53, the tumour scores were based on the method described by Isola et al (1992) . Tumours were scored as strongly positive if more than 20% of the nuclei were stained. hImmunostaining in more than 20% of the tumour cells was taken to represent p53 protein overexpression. If only a small proportion of the nuclei were stained (1-20%), the tumour was scored weakly positive.
Weakly positive and negative tumours were not included in statistical analysis. Oestrogen receptor expression was considered positive when more than 10% of the tumour cells demonstrated positive nuclear staining and negative when less than 10% stained (Pertschuk et al, 1990) . This method was used because it has been demonstrated to be more predictive of patients' prognosis.
The chi-squared analysis (contingency tables) was performed to assess the significance of association between expression of c-erbB3 and clinicopathological parameters and other tumour markers. Statistical Graphics System Version 5.0 was used to conduct the correlation tests. The level of significance used throughout the statistical test was 0.05 (5%).
RESULTS
In the present study. expression of c-erbB3 protein was detected using two monoclonal antibodies, RTJ1 and RTJ2. We observed identical staining for both the antibodies. In general. heterogeneous reactivity. The staining for c-erbB3 detected by both the antibodies was predominantly cytoplasmic, with none of the tumours exhibiting membrane immunoreactivity. The staining was finely granular throughout the cytoplasm of the malignant Immunopositivity of c-erbB3 was evaluated in comedo DCIS, invasive ductal carcinomas, carcinomas with combined lesions (in situ and invasive ductal component) and invasive lobular carcinomas. Our data indicated that six (67%) of the nine comedo DCIS were strongly positive for c-erbB3 protein. No weak staining was seen in the in situ carcinomas. Of the 84 invasive ductal carcinomas, 44 (52%) showed strong immunopositivity, whereas seven (8%) showed weak staining. Among the four invasive lobular carcinomas, one (25%) was strongly stained and three (75%) were weakly stained. Immunoreactivity of c-erbB3 protein was also observed in five (71 %) of seven cases in which comedo DCIS was adjacent to the invasive ductal component. In these cases, both the in situ and the invasive component were strongly positive. No weak staining was observed. Table 1 summarizes the relationship between c-erbB3 expression (detected by RTJ 1 and RTJ2) and prognostic factors including (Rajkumar et al, 1993) . The superior perfonnance of RTJ 1 could be due to it being an IgM antibody with ten potential combining sites and a high avidity for multiple copies of the c-erbB3 protein in tissue sections (Rajkumar et al, 1993) . RTJ2, an IgGl monoclonal antibody directed against the same peptide (49.3 kDa) , gave an identical immunohistochemical staining pattern with tissues which had earlier been stained with RTJ1 (Rajkumar et al, 1993) and rabbit polyclonal antibody . Furthermore, RTJ2 has been shown to be specific for c-erbB3 protein as determined by Western blotting, immunoprecipitation and immunocytochemistry. Lemoine et al (1992a) (Lemoine et al, 1992a ) demonstrated an identical staining reaction when stained with the polyclonal antibody (Lemoine et al, 1992a) and RTJ1. As RTJI and RTJ2 gave concordant results and identical staining pattems which were also indicated by the present study, the cytoplasmic staining of RTJ1 could not be due to nonspecific reaction or cross-reaction. In a recent paper on a larger study with RTJ1, Travis et al (1996) (1992) , using polyclonal antibody and a smaller sample size, demonstrated that 13 of 14 primary breast carcinomas were positive for c-erbB3 immunoreactivity but failed to describe the staining intensity of the positive cells. This makes it difficult to interpret their data Using RTJ1, these authors had shown that the staining was observed to be predominantly cytoplasmic. has suggested that there is a possibility that the majority of c-erbB3 protein at any one time is present in intracellular pools. Initially, it had been thought that the cytoplasmic immunoreactivity of c-erbB2 was non-specific (de Potter et al, 1989 ). However, Kumar et al (1991) had reported that only about 20% of the total c-erbB2 protein expressed in SKBR-3 breast cancer cells was located on the cell surface, the remainder being in other intracellular fractions. In addition, Coombs et al (1993) had shown that the cytoplasmic staining for c-erbB2 can be blocked by the immunizing peptide, suggesting that this represents expression of the c-erbB2 protein. This could also be one of the possibilities for c-erbB3. In contrast, Gasparini et al (1994) , using the same antibody (RTJ1), has reported that 65% of the node-negative breast carcinomas showed staining of cell membranes, but 13% showed strong positivity and a much higher percentage (89%) showed cytoplasmic staining. In addition, the authors have indicated that there is a highly significant association between membrane and cytoplasmic staining. In common with other findings, the present data showed that these antibodies (RTJ1 and RTJ2) locate the c-erbB3 protein mainly in the cytoplasm, suggesting that cytoplasmic immunoreactivity may be significant. The high proportion of breast carcinomas with strongly expressed c-erbB3 indicates that the gene may have an important role in breast tumorigenesis.
Of the nine ductal carcinoma in situ of comedo subtype, six (67%) showed overexpression of c-erbB3 gene product.
Interestingly, ductal cacinoma in situ has been shown to be a precursor of invasive carcinomas, because it is frequently present in tissues adjacent to breast cancer and is associated with the presence of invasive carcinoma in the same region of the same breast where the DCIS was found (Page et al, 1982; Betsill et al, 1987) . Comedo DCIS, a subtype of DCIS, has been associated with a higher rate of proliferation, as determined by thymidine labelling index (TLI), compared with other subtyps of DCIS (Meyer, 1986) . Furthermore, features such as comedo subtype have been demonstrated to be associated with local recurrence and progression to invasive breast cancer (Lagios et al. 1989; Lagios, 1990) . This implies that comedo DCIS are biologically aggressive neoplasms.
Based on these observations, we suggest that expression of c-erbB3 may be up-regulated during the preinvasive stages and could be an important pathogenic factor in early events of breast malignancies.
In addition, we have demonstae that five (71%) out of seven cases in which comedo DCIS were present adjacent to the invasive Britsh Joumal of Cancer (1998) 78 (10), [1385] [1386] [1387] [1388] [1389] [1390] 0 Cancer Research Campaign 1996 C-erbB3 in breast cancer 1389 component were strongly stained for c-erbB3 protein in both the lesions. Similarly. Poller et al ( 1992) al ( 1996) and Quinn et al ( 1994) did not find any association between c-erbB3 and c-erbB2. Gasparini et al (1994) found a significant association with c-erbB2 in nodenegative breast carcinoma patients. which is different from the group of patients in the present study. We have documented that a high percentage of EGFR-positive (67%7c). c-erbB2-positive (67%). pS3-positive (75%c) and cathepsin-D-positive (6(%)%) DCIS were strongly positive for c-erbB3. Recent studies have shown that transfection of cells with c-erbB3 and c-erbB2 reconstitutes a higher affinity binding, receptor. which is capable of goenerating a tyrosine phosphory-lation signal in response to heregulim. Furthermore. in cells expressing c-erbB2 and c-erbB3. both proteins become tyrosine phosphorylated upon interaction with heregulin (Sliwkowski et al. 1994 ). This heregulin-stimulated phosphorvlation of c-erbB3 is likely mediated bv cross-phosphorylation of the c-erbB3 protein by the c-erbB2 receptor tvTosine kinase (Kim et al. 1994 : Sliw-kowski et al. 1994 . It also has been shown that the bindinc of epidermal growth factor (EGF) to the EGFR results in the activation of its protein tyrosine kinase activity and the phosphorylation of the c-erbB3 protein on tyTosine residues (Kim et al. 1994) . From various studies. it has been noted that overexpression of EGFR and cathepsin-D has been associated with poor prognosis (Lewis et al. 1990 : Nicholson et al. 1990 : Tandon et al. 1990 : Winstanley et al. 1993 . suggesting that coexpression of c-erbB3 protein and these tumour markers in the same tumours mav be useful to predict the outcome or status of the disease.
Presence of high levels of c-erbB3 in non-invasive. non-invasive and invasive in the same lesions and invasive carcinomas may indicate that c-erbB3 could be involved in the progression of tumours from preinvasive to invasive stare. Furthermore. its association with established prognostic factors such as histologrical arade and with tumour markers includinc EGFR and cathepsin-D may suggest that c-erbB3 could have potential to be a prognostic indicator for breast cancer. However. other studies on a greater number of patients. with clinical follow-up. are needed to demonstrate the usefulness of this new marker.
